FDA Issues Long-Planned Draft Guidance On Functional Indications For ICDs
This article was originally published in The Gray Sheet
Manufacturers who wish to describe the benefits of ICDs in a particular patient population in the device labeling must submit a PMA supplement to FDA with supporting data, according to a 1draft guidance
You may also be interested in...
FDA is crafting a "functional indications" policy to help agency staff and implantable cardioverter defibrillator manufacturers clarify the devices' intended patient population
FDA would still need to consider on a case-by-case basis whether a premarket approval application supplement would be required for manufacturers to promote new indications for implantable cardioverter defibrillators (ICDs) under the agency's proposed labeling change for the devices.
Dr Reddy's is poised to expand its OTC offering in Russia and certain CIS countries by snapping up a basket of allergy brands from fellow Indian firm Glenmark.